Eli Lilly and Company revealed plans in early February 2026 to acquire Orna Therapeutics, a cutting-edge biotech company specializing in in vivo cell therapies, for up to $2.4 billion. This deal marks Lilly’s bold entry into next-generation CAR-T treatments using circular RNA and lipid nanoparticle technologies.
Deal Overview
The transaction includes an upfront cash payment to Orna shareholders, supplemented by milestone payments linked to clinical and regulatory achievements. Orna’s proprietary platforms enable CAR-T cell engineering directly inside patients, simplifying production and targeting autoimmune diseases like those driven by B cells. Lead programs, such as ORN-252 against CD19, were advancing toward human trials at the time of announcement.
Leadership Insights
Eli Lilly’s executive vice president of immunology emphasized the strategic fit: “Orna’s innovative in vivo approach has the potential to transform how we treat immune disorders, building on our momentum in genetic medicines.” Orna Therapeutics CEO Joe Bolen, Ph.D., added, “Our circular RNA technology, combined with advanced delivery systems, could deliver more potent and accessible therapies—partnering with Lilly accelerates this vision for patients worldwide.”
Broader Implications
This acquisition strengthens Lilly’s pipeline amid fierce competition from firms like AstraZeneca in the in vivo CAR-T space. It follows Lilly’s robust 2025 performance, fueled by blockbuster drugs such as Mounjaro and Zepbound, positioning the company for growth in immunology and beyond. The deal awaits standard regulatory clearances and is expected to close soon.
By
